• Matthew Stachowiak

PD-L1 Companion Diagnostics and Scoring Systems

Updated: Aug 27, 2020

FDA Approvals with PD-L1 Companion Diagnostics

Recently, FDA approved two new immunotherapies with PD-L1 based companion diagnostics, both for the first-line treatment of metastatic non-small cell lung cancer (NSCLC).

(1) Combination therapy nivolumab + ipilimumab, for PD-L1 expression >= 1%, and

(2) atezolizumab for high expression of PD-L1 (IC >= 10% or TC >= 50%)

Prior to these approvals, pembrolizumab was the only drug with a PD-L1 based companion diagnostic in NSCLC (based on TPS score >= 1%).

Previously, atezolizumab had PD-L1 based companion diagnostic for two other diseases -- urothelial carcinoma and triple negative breast cancer. Also, atezolizumab (in combination with chemotherapy), nivolumab, and nivolumab + ipilimumab had other approvals for NSCLC, but these were all regardless of PD-L1 expression levels.

The following table shows the new set of PD-L1 companion diagnostics and associated scoring systems as of 5/31/2020:

There are now three therapies with five different scoring systems for PD-L1 companion diagnostics. Three of the scoring systems are based on the percentage of tumor cells with PD-L1 staining (TPS, TC, % PD-L1 Expression), and seem to have equivalent definitions. IC is based on PD-L1 expression in tumor-infiltrating immune cells, while CPS (the only scoring system that is a number rather than a percentage) counts PD-L1 staining in both tumor cells and non-tumor cells.

Combined PD-L1 and NGS reporting

In my experience, most often PD-L1 results are reported and interpreted separately from NGS results. However, at GenomOncology, a growing number of our clients combine PD-L1 results and NGS results into a single report. This has a few advantages:

  1. Simplicity. A single report with a unified interpretation.

  2. Individual therapy indications involve both PD-L1 and NGS results. For example, both new approvals for NSCLC (atezolizumab and nivolumab + ipilimumab) require the tumor to be negative for ALK fusion and EGFR mutations, in addition to the companion diagnostic requirement for PD-L1.

  3. Therapy selection depends on synthesizing PD-L1 and NGS results. Even when a patient is eligible for an immune checkpoint inhibitor according to the FDA label (e.g. PD-L1 expression + ALK negative + EGFR negative), if there is another oncogenic driver present such as BRAF V600E, ROS1/RET fusion, or MET exon 14 skipping, NCCN Guidelines recommend selecting a therapy based on that driver, instead of treating with the immune checkpoint inhibitor. A combined report can better convey this information.

PD-L1 Scores in Decision Support Software

In order to support our clients who report PD-L1 alongside NGS results, GenomOncology software handles PD-L1 scoring. The PD-L1 result for a given assay can be expressed as a single "alteration concept" that includes both the scoring system and the measured score result. For example:

  • PD-L1 Expression (TPS = 60%)

  • PD-L1 Expression (CPS = 3)

  • PD-L1 Expression (IC = 8%)

Our content team curates "therapy assertions" that indicate the range of valid scores. For example, this is a screenshot of the PD-L1 based pembrolizumab approval for HNSCC:

The GenomOncology Match Algorithm then ensures that any particular PD-L1 result matches properly to the appropriate therapies.

Please reach out to with any questions.

945 views0 comments

Recent Posts

See All

Updating Content in the GO Precision Oncology Platform

The field of precision medicine is rapidly evolving. Treatment options that are available for cancer patients are changing every day due to the release of new therapy approvals, or as new clinical tri


1138 West 9th St Suite 400

Cleveland, OH 44113, USA

(440) 617-6087


© 2021 GenomOncology LLC